Login
News
Tenofovir gel reduces risk of HIV and HSV infection in a clinical trial
20 July 2010Potent HIV entry inhibitor identified in bananas
19 March 2010Influenza vaccine composition for 2010-2011 season
09 March 2010Conferences
26th International Human Papillomavirus Conference and Clinical Workshop
XVIII International AIDS Conference (AIDS 2010)
BIT's 3rd Annual World Summit of Antivirals (WSA-2010)
50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Abbreviations
| Name | Description |
|---|---|
| 3A IN | Inhibitor of Rhinovirus protein 3A |
| a-gluco IN | Alpha-glucosidase I inhibitor |
| AASLD | American Association for the Study of Liver Diseases |
| ACE | Angiotensin-converting enzyme |
| ACIP | Advisory Committee on Immunization Practices |
| ACTG | AIDS Clinical Trials Group |
| ADCC | Antibody-dependent cellular cytotoxicity |
| ADME | Absorption, distribution, metabolism, excretion |
| AE | Adverse event |
| AGIN | Anogenital intraepithelial neoplasia |
| AK | Adenylate kinase |
| ALT | Alanine aminotransferase enzyme (marker of liver injury) |
| ANRS | Agence Nationale de Recherche sur le SIDA |
| API | Active pharmaceutical ingredient |
| Approx. | Approximately |
| ARV | Antiretroviral (drug) |
| AST | Aspartate aminotransferase enzyme, marker of liver injury |
| AVEG | AIDS Vaccine Evaluation Group |
| BBB | Blood-brain barrier |
| BCG | Bacille Calmette-Guérin |
| BID | Bis in die (twice daily) |
| BLA | Biologics License Application |
| BPV | Bovine Papillomavirus (member of Papillomaviridae family) |
| BVDV | Bovine Viral Diarrhea virus (member of Flaviviridae family) |
| CANVAC | Canadian Network for Vaccines and Immunotherapeutics |
| CCHFV | Crimean-Congo Haemorrhagic Fever virus (member of Bunyaviridae family) |
| CCIC50 | Cell culture inhibitory concentration 50%: concentration of drug inducing 50% cell killing (measure of cytotoxicity) |
| CCID50 | Cell culture infective dose 50%: viral dose infecting 50% of cells (better known as TCID50) |
| CDC | Centers for Disease Control and Prevention (USA) |
| cdk IN | Inhibitor of cellular cyclin-dependent kinase |
| cGMP | Current Good Manufacturing Practices |
| CHMP | Committee for Human Medicinal Products (EU) |
| CIN | Cervical intraepithelial neoplasia |
| CMV | Cytomegalovirus (member of Herpesviridae family) |
| CNS | Central nervous system |
| co-mktg | Co-marketing |
| cp | Cold-passaged (viral variant obtained by serial passage at low temperature) |
| CPE | Cytopathic effects (in cell culture) |
| cpnd | Compound |
| CSF | Colony-stimulating factors |
| CTA | Clinical Trial Authorization, European equivalent of IND in the US |
| CTL | Cytotoxic T-lymphocyte |
| Cyclophil IN | Inhibitor of cellular cyclophilin |
| dCK | Deoxycytidine kinase |
| dCK | Deoxycytidine kinase |
| ddRNAi | DNA-directed interfering ribonucleic acid |
| dGK | Deoxyguanosine kinase |
| DHEA | Dehydroepiandrosterone |
| DHHS | U.S. Department of Health and Human Services |
| DHS IN | Inhibitor of cellular deoxyhypusine synthase |
| DKA | Diketo acid |
| dL | Deciliter |
| DNA | Deoxyribonucleic acid |
| DNA Pol IN | DNA polymerase inhibitor |
| DOHH IN | Inhibitor of cellular deoxyhypusine hydroxylase |
| dsDNA | Double-stranded deoxyribonucleic acid |
| DSMB | Data Safety Monitoring Board |
| dsRNA | Double-stranded ribonucleic acid |
| DTaP | Diphtheria, tetanus, acellular pertussis (vaccine) |
| DTH | Delayed-type hypersensitivity |
| DTT | Dithiothreitol |
| DTwP | Diphtheria, tetanus, whole cells pertussis (vaccine) |
| EASL | European Association for the Study of the Liver |
| EBV | Epstein-Barr virus (member of Herpesviridae family) |
| EC50 | Effective concentration 50% in virus-infected cell culture: concentration of drug which reduces viral replication by 50% |
| ECG | Electrocardiogram |
| EEE | Eastern Equine Encephalitis virus (member of Togaviridae family) |
| EI | Entry inhibitor |
| EIF | Elongation initiation factor |
| eIPV | Enhanced potency inactivated Poliovirus vaccine |
| eiRNA | Expressed interfering ribonucleic acid |
| EMEA | European Medicines Evaluation Agency (EU) |
| Encaps IN | Encapsidation inhibitor |
| env | Retroviral gene encoding envelope glycoproteins |
| enz. | Enzyme |
| ERIG | Equine anti-Rabies immunoglobulins |
| EU | European Union |
| EVR | Early virologic response |
| Exp. | Expiration |
| expr | Expression |
| FBS | Fetal bovine serum |
| FDA | Food and Drug Administration (USA) |
| FFU | Focus-forming units |
| fm | Femtomolar (10-15 M) |
| g | Gram |
| gag | “Group-specific antigen”, retroviral gene encoding core/nucleocapsid structural proteins |
| GBV-B | GB virus B, infecting New World monkeys and closely related to HCV (member of Flaviviridae family) |
| GI | Gastro-intestinal |
| GMP | Guanosine monophosphate |
| gp120 | Glycoprotein 120, HIV-specific envelope glycoprotein with molecular weight 120 kD, involved in attachment to cell receptor for viral entry |
| GR | Glucocorticoid receptor |
| GSH | Glutathione |
| GTP | Guanosine triphosphate |
| h | Hour |
| HA | Hemagglutinin |
| HAART | Highly active antiretroviral therapy |
| HAI | Inhibition of hemagglutination (assay) |
| HAV | Hepatitis A virus (member of Picornaviridae family) |
| HBIG | Hepatitis B virus immunoglobulins |
| HBV | Hepatitis B virus (member of Hepadnaviridae family) |
| HCV | Hepatitis C virus (member of Flaviviridae family) |
| HDAC1 IN | Inhibitor of cellular histone deacetylase I enzyme |
| HDCV | Human diploid cell vaccine (obtained by propagating virus in cultures of human diploid cells) |
| HDV | Hepatitis delta virus (not currently assigned to a viral family) |
| HEC | Hydroxyethyl cellulose |
| Hel IN | Helicase inhibitor |
| Hel-Pri IN | Helicase-primase complex inhibitor |
| HEP | High egg passage |
| HEV | Hepatitis E virus (not currently assigned to a viral family) |
| HHV-1 | Human Herpes virus 1, or Herpes simplex type 1 (HSV-1, Herpesviridae) |
| HHV-2 | Human Herpes virus 2, or Herpes simplex type 2 (HSV-2, Herpesviridae) |
| HHV-3 | Human Herpes virus 3, or Varicella-Zoster virus (VZV, Herpesviridae) |
| HHV-4 | Human Herpes virus 4, or Epstein-Barr virus (EBV, Herpesviridae) |
| HHV-5 | Human Herpes virus 5, or human Cytomegalovirus (CMV, Herpesviridae) |
| HHV-8 | Human Herpes virus 8, or Kaposi’s Sarcoma Associated Herpesvirus (KSHV, Herpesviridae) |
| Hib | Haemophilus influenzae type b |
| HIV | Human Immunodeficiency virus (member of Retroviridae family) |
| HLA | Human leukocyte antigens |
| HPV | Human Papillomavirus (member of Papillomaviridae family) |
| HR | Heptad repeat |
| HRIG | Human Rabies immunoglobulins |
| HRV | Human Rhinovirus (member of Picornaviridae family) |
| HSV | Herpes simplex virus (member of Herpesviridae family); HSV-1, Herpes simplex virus type 1; HSV-2, Herpes simplex virus type 2 |
| HVTN | HIV Vaccine Trials Network |
| IAS-USA | International AIDS Society - USA |
| IAVI | International AIDS Vaccine Initiative |
| IC50 | Inhibitory concentration 50: concentration of inhibitor needed to achieve 50% inhibition of an enzymatic reaction |
| ICAM-1 | Intercellular Adhesion Molecule 1 |
| IDE | Investigational Device Exemption (US) |
| IFN | Interferon |
| Ig | Immunoglobulin |
| IgA | Immunoglobulin A |
| IgG | Immunoglobulin G |
| IgM | Immunoglobulin M |
| II | Integrase inhibitor |
| IL | Interleukin |
| IM | Intramuscular |
| IMPDH | Inosine 5’-monophosphate dehydrogenase (needed to assure adequate intracellular pool of guanosine triphosphate) |
| IMPDH IN | IMPDH inhibitor |
| IND | Investigational New Drug (US) |
| Inhib. | Inhibition |
| Ion IN | Ion-channel forming protein (viroporin) inhibitor |
| IP | Intellectual property |
| IPV | Inactivated Poliovirus (or poliomyelitis) vaccine |
| IRES | Internal ribosome entry site |
| IRES IN | Internal ribosome entry site inhibitor |
| IV | Intravenous |
| JEV | Japanese Encephalitis virus (member of Flaviviridae family) |
| kD | Kilodalton (1000 daltons) |
| kg | Kilogram |
| Ki | Constant of inhibition: measure of enzyme inhibition based on reaction kinetics |
| KS | Kaposi’s Sarcoma |
| KSHV | Kaposi’s Sarcoma-Associated Herpesvirus (HHV-8, member of Herpesviridae family) |
| LCMV | Lymphocytic choriomeningitis virus (member of Arenaviridae family) |
| LD50 | Lethal dose 50 (dose associated with 50% mortality in animals) |
| LEP | Low egg passage |
| LRTI | Lower respiratory tract infection |
| M | Molar |
| m | Meter |
| MAA | Marketing Authorization Application (EU) |
| MDR | Multi-drug resistance |
| MEP | Multi-Epitope Peptide |
| mg | Milligram (10-3 g) |
| MHC | Major histocompatibility complex |
| MHRA | Medicines and Healthcare products Regulatory Agency (UK) |
| MI | Maturation inhibitor |
| min. | Minutes |
| mktg | Marketing |
| mL | Milliliter |
| mM | Millimolar (10-3 M) |
| mm | Millimeter (10-3m) |
| MMR | Measles, Mumps and Rubella combined vaccine |
| MOPV | Monovalent oral Poliovirus vaccine |
| MPL | Monophosphoryl lipid A, proprietary adjuvant used with certain vaccines |
| MPV | Metapneumovirus (member of Paramyxoviridae family) |
| mRNA | Messenger ribonucleic acid |
| MTP-PE | Muramyl tripeptide (adjuvant) |
| MuLV | Murine Leukemia virus (member of Retroviridae family) |
| MVA | Modified Vaccinia Ankara (Poxvirus vector obtained by modifying Ankara strain of Vaccinia) |
| MW | Molecular weight |
| NA | Neuraminidase |
| NA IN | Neuraminidase inhibitor |
| NBE | New biological entity |
| NCE | New chemical entity |
| NCI | National Cancer Institute (US) |
| NcRTI | Nucleoside-competing reverse transcriptase inhibitor |
| NDA | New Drug Application (US) |
| NDS | New Drug Submission (Canada) |
| NDV | Newcastle Disease virus (member of Paramyxoviridae family) |
| NHS | National Health Service (UK) |
| NIAID | National Institute of Allergy and Infectious Diseases |
| NIBSC | National Institute for Biological Standards and Control (UK) |
| NIDDK | National Institute of Diabetes and Digestive and Kidney Diseases |
| NIH | National Institutes of Health (US) |
| NIID | National Institute of Infectious Diseases (Japan) |
| NIMH | National Institute of Mental Health (US) |
| NK | Natural killer (cells) |
| nM | Nanomolar (10-9 M) |
| nm | Nanometer (10-9 m) |
| NNRTI | Non-nucleoside reverse transcriptase inhibitor |
| NRTI | Nucleoside reverse transcriptase inhibitor |
| NS5A IN | Inhibitor of HCV non-structural NS5A phosphoprotein involved in RNA replication complex and pathogenesis |
| NSI | Non-syncytium inducing |
| OBT | Optimized background therapy |
| OD | Orphan Drug (designation or status, US) |
| OMP | Orphan Medicinal Product (EU) |
| OPV | Oral Poliovirus (or poliomyelitis) vaccine |
| ORF | Open reading frame |
| OTC | Over-the-counter (drug available without prescription) |
| PAHO | Pan-American Health Organization |
| PAM | Protease-associated mutations (mutations in viral protease gene associated with resistance to PIs) |
| PARP IN | Inhibitor of cellular poly-ADP ribose polymerase |
| PATH | Program for Appropriate Technology in Health |
| PBMC | Peripheral blood monocyte cells |
| PCECV | Primary chick embryo cell vaccine (obtained by propagation of virus in cultures of chicken fibroblasts) |
| PCPP | Polyphosphazene (adjuvant for certain vaccines) |
| PD | Pharmacodynamics |
| PDEV | Purified duck embryo vaccine (obtained by inoculation of virus into embryonated egg, with preparation of vaccine from egg material) |
| PED | Pediatric exclusivity |
| PEG | Polyethylene glycol |
| PEG-IFN | Pegylated interferon |
| PEP | Post-exposure prophylaxis |
| PFU | Plaque-forming units |
| PI | Protease inhibitor |
| PIC | Pre-integration complex |
| PIC IN | Inhibitor of pre-integration complex |
| PIV | Parainfluenza virus (member of Paramyxoviridae family) |
| PK | Pharmacokinetics |
| pM | Picomolar (10-12 M) |
| PML | Progressive multifocal leukoencephalopathy |
| PNA | Peptide-nucleic acid |
| pol | Retroviral gene encoding reverse transcriptase/RNAseH, protease and integrase enzymes |
| PPRTI | Pyrophosphate reverse transcriptase inhibitor |
| PR | Protease enzyme |
| PRP-T | Polyribosylribitol phosphate (PRP, main component of Haemophilus influenzae outer capsule) conjugated to tetanus toxoid |
| pts | Patients |
| PVRV | Purified Vero cell Rabies vaccine (obtained by propagation of virus in cultures of Vero cells) |
| QD | Once daily |
| Regul IN | Inhibitor of viral regulatory protein or gene |
| Release IN | Inhibitor of virion release from infected cells |
| RIG | Human Rabies immunoglobulins |
| RNA | Ribonucleic acid |
| RNA Pol IN | RNA polymerase inhibitor |
| RNAi | Ribonucleic acid interference |
| RNAse | Ribonuclease |
| RRP | Recurrent respiratory papillomatosis, caused by some members of Papillomaviridae family |
| RSV | Respiratory Syncytial virus (member of Paramyxoviridae family) |
| RT | Reverse transcriptase enzyme |
| RT-like IN | Inhibitor of reverse transcriptase-like enzyme |
| RTI | Reverse transcriptase inhibitor |
| RVFV | Rift Valley Fever virus (member of Bunyaviridae family) |
| RVR | Rapid virologic response |
| SAAVI | South African AIDS Vaccine Initiative |
| SAE | Serious adverse event |
| SARS | Severe Acute Respiratory Syndrome (caused by member of Coronaviridae family) |
| SAVI | SARS Accelerated Vaccine Initiative |
| sc | Subcutaneous |
| SCID | Severe combined immunodeficiency |
| SDF-1 | Stromal cell-derived factor-1 (also called CXCL12), natural ligand for CXCR4 cell co-receptor used by HIV for viral entry |
| SI | Syncytium-inducing |
| siRNA | Small interfering ribonucleic acid |
| SIV | Simian Immunodeficiency virus |
| SLEV | St-Louis Encephalitis virus (member of Flaviviridae family) |
| SMBV | Suckling mouse brain vaccine (obtained by intracerebral inoculation of virus and preparation of vaccine directly from mouse brain tissue) |
| ssDNA | Single-stranded deoxyribonucleic acid |
| SSPE | Subacute sclerosing panencephalitis |
| ssRNA | Single-stranded ribonucleic acid |
| STD | Sexually transmitted diseases |
| STI | Structured (or Strategic) Treatment Interruption |
| SV40 | Simian virus 40 (member of Polyomaviridae family) |
| SVM | Selective viral mutagenesis |
| SVR | Sustained virologic response |
| TAM | Thymidine analogue mutations (mutations in HIV reverse transcriptase gene associated with drug resistance, selected for by thymidine analogues azidothymidine and stavudine) |
| TAR | Tat-responsive element |
| TB | Tuberculosis |
| TBEV | Tick-Borne Encephalitis virus (member of Flaviviridae family) |
| TCID50 | Tissue culture infective dose 50%: viral dose infecting 50% of cells (sometimes called CCID50) |
| Th1 | Cellular arm of immune system |
| Th2 | Humoral arm of immune system |
| TID | Ter un die (three times per day) |
| TK | Thymidine kinase enzyme |
| TLR | Toll-like receptor |
| TNF | Tumor necrosis factor |
| TOPV | Trivalent oral Poliovirus (or poliomyelitis) vaccine |
| tRNA | Transfer ribonucleic acid |
| ts | Temperature-sensitive |
| U | Unit |
| UCK-1 | Uridine-cytidine kinase 1 |
| UMMS | University of Massachusetts Medical School |
| Uncoat IN | Inhibitor of viral uncoating in entry process |
| USAFEB | US Armed Forces Epidemiological Board (during World War II) |
| USAMRIID | US Army Medical Research Institute of Infectious Diseases |
| USAMRMC | US Army Medical Research and Materiel Command |
| VAPP | Vaccine-associated paralytic poliomyelitis |
| VEE | Venezuelan Equine Encephalitis virus (member of Togaviridae family) |
| VIG | Vaccinia immunoglobulins |
| VLP | Virus-like particles |
| VRC | Vaccine Research Center |
| vs | versus |
| VSV | Vesicular Stomatitis virus (member of Rhabdoviridae family) |
| VZIG | Varicella-Zoster immunoglobulins |
| VZV | Varicella-Zoster virus (member of Herpesviridae family) |
| WEE | Western Equine Encephalitis virus (member of Togaviridae family) |
| WHO | World Health Organization |
| WNV | West Nile virus (member of Flaviviridae family) |
| WRAIR | Walter Reed Army Institute of Research |
| wt or WT | Wild-type |
| WWII | World War II |
| YFV | Yellow Fever virus (member of Flaviviridae family) |
| YMPK | Uridine-cytidine monophosphate kinase (UMP-CMP kinase) |
| ZFN | Zinc-finger protein nuclease |
| Zn-f IN | Zinc-finger inhibitor |
| µg | Microgram (10-6 g) |
| µM | Micromolar (10-6 M) |
| µm | Micrometer or micron (10-6 m) |